PAM-1: an Antimicrobial Peptide with Promise Against Ceftazidime-avibactam Resistant Infection

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 May 20

PMID 38765679

Authors

Yijia Han

Yi Zhang

Xiaodong Zhang

Zeyu Huang

Jingchun Kong

Xiuxiu Wang

Lijiang Chen

Yue Wang

Jianming Cao

Tieli Zhou

Mo Shen

Affiliations

Soon will be listed here.

Abstract

Introduction: Antibiotic misuse and overuse have led to the emergence of carbapenem-resistant bacteria. The global spread of resistance to the novel antibiotic combination ceftazidime-avibactam (CZA) is becoming a severe problem. Antimicrobial peptide PAM-1 offers a novel approach for treating infections caused by antibiotic-resistant bacteria. This study explores its antibacterial and anti-biofilm activities and mechanisms against CZA-resistant , evaluating its stability and biosafety as well.

Methods: The broth microdilution method, growth curve analysis, crystal violet staining, scanning electron microscopy, and propidium iodide staining/N-phenyl-1-naphthylamine uptake experiments were performed to explore the antibacterial action and potential mechanism of PAM-1 against CZA-resistant E. coli. The biosafety in diverse environments of PAM-1 was evaluated by red blood cell hemolysis, and cytotoxicity tests. Its stability was further assessed under different temperatures, serum concentrations, and ionic conditions using the broth microdilution method to determine its minimum inhibitory concentration (MIC). Galleria mellonella infection model and RT-qPCR were used to investigate the in vivo antibacterial and anti-inflammatory effects.

Results And Discussion: antibacterial experiments demonstrated that the MICs of PAM-1 ranged from 2 to 8 μg/mL, with its effectiveness sustained for a duration of 24 h. PAM-1 exhibited significant antibiofilm activities against CZA-resistant ( < 0.05). Furthermore, Membrane permeability test revealed that PAM-1 may exert its antibacterial effect by disrupting membrane integrity by forming transmembrane pores ( < 0.05). Red blood cell hemolysis and cytotoxicity tests revealed that PAM-1 exerts no adverse effects at experimental concentrations ( < 0.05). Moreover, stability tests revealed its effectiveness in serum and at room temperature. The Galleria mellonella infection model revealed that PAM-1 can significantly improve the survival rate of (>50%)for treatment. Lastly, RT-qPCR revealed that PAM-1 downregulates the expression of inflammatory cytokines ( < 0.05). Overall, our study findings highlight the potential of PAM-1 as a therapeutic agent for CZA-resistant infections, offering new avenues for research and alternative antimicrobial therapy strategies.

Citing Articles

Advancing Nanotechnology: Targeting Biofilm-Forming Bacteria with Antimicrobial Peptides.

Campos J, Pontes J, Canales C, Roque-Borda C, Pavan F BME Front. 2025; 6:0104.

PMID: 40041091 PMC: 11876546. DOI: 10.34133/bmef.0104.

References

Hong M, Kim M, Park Y . Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against . Int J Mol Sci. 2021; 22(11). PMC: 8197367. DOI: 10.3390/ijms22115540. View

Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi M, Rescigno M . TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010; 29(13):2242-52. PMC: 2905255. DOI: 10.1038/emboj.2010.94. View

Livermore D, Meunier D, Hopkins K, Doumith M, Hill R, Pike R . Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. J Antimicrob Chemother. 2017; 73(3):648-657. DOI: 10.1093/jac/dkx438. View

Peleg A, Hooper D . Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362(19):1804-13. PMC: 3107499. DOI: 10.1056/NEJMra0904124. View

Xu W, Chen T, Wang H, Zeng W, Wu Q, Yu K . Molecular Mechanisms and Epidemiology of Fosfomycin Resistance in Isolated From Patients at a Teaching Hospital in China. Front Microbiol. 2020; 11:1290. PMC: 7332539. DOI: 10.3389/fmicb.2020.01290. View

van Duin D, Arias C, Komarow L, Chen L, Hanson B, Weston G . Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020; 20(6):731-741. PMC: 7473597. DOI: 10.1016/S1473-3099(19)30755-8. View

Kaczynska K, Kogut E, Zajac D, Jampolska M, Andrzejewski K, Sulejczak D . Neurotensin-based hybrid peptide's anti-inflammatory activity in murine model of a contact sensitivity response. Eur J Pharm Sci. 2016; 93:84-9. DOI: 10.1016/j.ejps.2016.08.012. View

Wang J, Wong E, Whitley J, Li J, Stringer J, Short K . Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. PLoS One. 2011; 6(8):e24030. PMC: 3166071. DOI: 10.1371/journal.pone.0024030. View

Le Thanh Nguyen H, Trujillo-Paez J, Umehara Y, Yue H, Peng G, Kiatsurayanon C . Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis. Int J Mol Sci. 2020; 21(20). PMC: 7589391. DOI: 10.3390/ijms21207607. View

10.

Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A . Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016; 22(5):444-50. DOI: 10.1016/j.cmi.2016.01.016. View

11.

Flemming H, Wingender J, Szewzyk U, Steinberg P, Rice S, Kjelleberg S . Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016; 14(9):563-75. DOI: 10.1038/nrmicro.2016.94. View

12.

Ashfaq M, Dana D, Al-Ghouti M . Application of MALDI-TOF MS for identification of environmental bacteria: A review. J Environ Manage. 2021; 305:114359. DOI: 10.1016/j.jenvman.2021.114359. View

13.

Quintilla R, Kolecka A, Casaregola S, Daniel H, Houbraken J, Kostrzewa M . MALDI-TOF MS as a tool to identify foodborne yeasts and yeast-like fungi. Int J Food Microbiol. 2017; 266:109-118. DOI: 10.1016/j.ijfoodmicro.2017.11.016. View

14.

Dong N, Ma Q, Shan A, Lv Y, Hu W, Gu Y . Strand length-dependent antimicrobial activity and membrane-active mechanism of arginine- and valine-rich β-hairpin-like antimicrobial peptides. Antimicrob Agents Chemother. 2012; 56(6):2994-3003. PMC: 3370809. DOI: 10.1128/AAC.06327-11. View

15.

Shields R, Chen L, Cheng S, Chavda K, Press E, Snyder A . Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2016; 61(3). PMC: 5328542. DOI: 10.1128/AAC.02097-16. View

16.

Cornejo-Juarez P, Vilar-Compte D, Perez-Jimenez C, Namendys-Silva S, Sandoval-Hernandez S, Volkow-Fernandez P . The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis. 2014; 31:31-4. DOI: 10.1016/j.ijid.2014.12.022. View

17.

Yeaman M, Yount N . Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003; 55(1):27-55. DOI: 10.1124/pr.55.1.2. View

18.

Kim M, Kang H, Ko S, Hong M, Bang J, Seo C . Mechanisms driving the antibacterial and antibiofilm properties of Hp1404 and its analogue peptides against multidrug-resistant Pseudomonas aeruginosa. Sci Rep. 2018; 8(1):1763. PMC: 5789083. DOI: 10.1038/s41598-018-19434-7. View

19.

Azad M, Chen Y, Gibson S . Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2008; 11(4):777-90. DOI: 10.1089/ars.2008.2270. View

20.

Zeng W, Liao W, Zhao Y, Wang L, Shu H, Jia H . A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant . Front Microbiol. 2022; 13:956044. PMC: 9315207. DOI: 10.3389/fmicb.2022.956044. View